|
|
Viscount Pharma Inc. (Viscount) is dedicated to development of new innovative antiviral and anticancer products. Viral infections and cancer according to the World Health Organization are top priorities in terms of global healthcare needs. This Company’s particular focus in antivirals is on therapies for treatment of HIV, Hepatitis B, and Herpes infections. Viscount’s products are emerging from the Company’s proprietary Technology Platform. This platform is a combination of chemical engineering techniques designed to produce new powerful drugs with better than existing safety profiles. Viscount is focused on development of new innovative antiviral and anticancer products. The Company is capitalizing on its business model, clinical expertise of its scientific and regulatory advisors and its Technology Platform to develop drugs that can be used alone or in combination to treat a complex of serious diseases. The Company believes that potent and well-tolerated combination therapies will improve the quality of life in patients living with AIDS. The Company also believes that Hepatitis B may also be effectively treated with the combination therapy due to its ability to develop resistant strains. Additionally, the Company believes that there is a sizable demand for new anti-Herpes medications, which suppress the Herpes virus formation including resistant viruses. The Company further believes that there is an opportunity for development of universal and specific cancer therapy, which may be used in combination with cancer treatment methods that exist today.
[Home] [Contact Us]
|
